MedTrace Logo

PulseMagic™ TrueForce™ PAF NMPA Study

NCT07720557 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-07-22

No results posted yet for this study

Summary

This clinical investigation is intended to demonstrate safety and effectiveness of the PulseMagic™ TrueForce™ Ablation Catheter and the PulseMagic™Pulse Field Ablation (PFA) Generator, and Columbus™ 3D EP Navigation System with Pulsed Field Ablation Software for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).

Conditions

  • Atrial Fibrillation (AF)
  • Paroxysmal AF
  • Drug Refractory Paroxysmal Atrial Fibrillation
  • Atrial Arrhythmia

Interventions

DEVICE

PFA Ablation catheter

Deliver PF energy using the PulseMagic™ PFA system

Sponsors & Collaborators

  • Shanghai MicroPort EP MedTech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-10
Primary Completion
2028-07-01
Completion
2028-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07720557 on ClinicalTrials.gov